Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions

References

• Albano E, Vidali M. (2010). Immune mechanisms in alcoholic liver disease. Genes Nutr 5:141–7.
   PubMed Web of Science ®Google Scholar
• Azad AK, Rajaram MV, Schlesinger LS. (2014). Exploitation of the macrophage mannose receptor (cd206) in infectious disease diagnostics and therapeutics. J Cytol Mol Biol 1. doi: 10.13188/2325-4653.1000003
   PubMedGoogle Scholar
• Bieghs V, Trautwein C. (2013). The innate immune response during liver inflammation and metabolic disease. Trends Immunol 34:446–52.
   PubMed Web of Science ®Google Scholar
• Blanchard V, Gadkari RA, Gerwig GJ, et al. (2007). Characterization of the N-linked oligosaccharides from human chorionic gonadotropin expressed in the methylotrophic yeast Pichia pastoris. Glycoconj J 24:33–47.
   PubMed Web of Science ®Google Scholar
• Conrad E, Resch TK, Gogesch P, et al. (2014). Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice. Hepatology 59:1555–63.
   PubMed Web of Science ®Google Scholar
• Cui K, Yan G, Xu C, et al. (2015). Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice. J Hepatol 62:1311–8.
   PubMed Web of Science ®Google Scholar
• Dobashi H, Seki S, Habu Y, et al. (1999). Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells. Hepatology 30:430–6.
   PubMed Web of Science ®Google Scholar
• Guarda G, Braun M, Staehli F, et al. (2011). Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213–23.
   PubMed Web of Science ®Google Scholar
• Higuchi Y, Nishikawa M, Kawakami S, et al. (2004). Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm 287:147–54.
   PubMed Web of Science ®Google Scholar
• Hirata K, Maruyama T, Watanabe H, et al. (2010). Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. J Control Release 145:9–16.
   PubMed Web of Science ®Google Scholar
• Ikuta S, Chuang VT, Ishima Y, et al. (2010). Albumin fusion of thioredoxin–the production and evaluation of its biological activity for potential therapeutic applications. J Control Release 147:17–23.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Donlin LT. (2014). Regulation of type I interferon responses. Nat Rev Immunol 14:36–49.
   PubMed Web of Science ®Google Scholar
• Kogelberg H, Tolner B, Sharma SK, et al. (2007). Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology 17:36–45.
   PubMed Web of Science ®Google Scholar
• Krenkel O, Tacke F. (2017). Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17:306–21.
   PubMed Web of Science ®Google Scholar
• Lee KC, Lin HC, Huang YH, Hung SC. (2015). Allo-transplantation of mesenchymal stem cells attenuates hepatic injury through IL1Ra dependent macrophage switch in a mouse model of liver disease. J Hepatol 63:1405–12.
   PubMed Web of Science ®Google Scholar
• Lohse AW, Weiler-Normann C, Tiegs G. (2010). Immune-mediated liver injury. J Hepatol 52:136–44.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Rigante D, Giannini M, et al. (2016). Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders. Clin Exp Rheumatol 34:531–8.
   PubMed Web of Science ®Google Scholar
• Louvet A, Mathurin P. (2015). Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 12:231–42.
   PubMed Web of Science ®Google Scholar
• Maeda H, Hirata K, Watanabe H, et al. (2015). Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J Pharmacol Exp Ther 352:244–57.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Chuang VT, Otagiri M. (2016). Albumin fusion protein (Chapter 4). In: Otagiri M, Chuang VT, eds. Albumin in medicine. Singapore: Springer, 71–89.
   Google Scholar
• Mcgreal EP, Rosas M, Brown GD, et al. (2006). The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology 16:422–30.
   PubMed Web of Science ®Google Scholar
• Mittal SK, Roche PA. (2015). Suppression of antigen presentation by IL-10. Curr Opin Immunol 34:22–7.
   PubMed Web of Science ®Google Scholar
• Miyamura S, Imafuku T, Anraku M, et al. (2016). Comparison of posttranslational modification and the functional impairment of human serum albumin in commercial preparations. J Pharm Sci 105:1043–9.
   PubMed Web of Science ®Google Scholar
• Nakashima H, Kinoshita M, Nakashima M, et al. (2008). Superoxide produced by Kupffer cells is an essential effector in concanavalin A-induced hepatitis in mice. Hepatology 48:1979–88.
   PubMed Web of Science ®Google Scholar
• Oikawa T, Takahashi H, Ishikawa T, et al. (2007). Intrahepatic expression of the co-stimulatory molecules programmed death-1, and its ligands in autoimmune liver disease. Pathol Int 57:485–92.
   PubMed Web of Science ®Google Scholar
• Oseini AM, Sanyal AJ. (2017). Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 37 Suppl 1:97–103.
   PubMed Web of Science ®Google Scholar
• Petrasek J, Bala S, Csak T, et al. (2012). IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122:3476–89.
   PubMed Web of Science ®Google Scholar
• Petrasek J, Dolganiuc A, Csak T, et al. (2011). Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 53:649–60.
   PubMed Web of Science ®Google Scholar
• Roh YS, Park S, Kim JW, et al. (2014). Toll-like receptor 7-mediated Type I Interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology 60:237–49.
   PubMed Web of Science ®Google Scholar
• Saraiva M, O'Garra A. (2010). The regulation of IL-10 production by immune cells. Nat Rev Immunol 10:170–81.
   PubMed Web of Science ®Google Scholar
• Shaabani N, Duhan V, Khairnar V, et al. (2016). CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection. Cell Death Dis 7:e2446.
   PubMed Web of Science ®Google Scholar
• Tilg H, Kaser A, Moschen AR. (2006). How to modulate inflammatory cytokines in liver diseases. Liver Int 26:1029–39.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Szabo G. (2016). Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 64:955–65.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Yamasaki K, Kragh-Hansen U, et al. (2001). In vitro and in vivo properties of recombinant human serum albumin from Pichia pastoris purified by a method of short processing time. Pharm Res 18:1775–81.
   PubMed Web of Science ®Google Scholar
• Wree A, Eguchi A, Mcgeough MD, et al. (2014). NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59:898–910.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Lötzerich M, Schaefer A, et al. (2003). IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J Immunol 171:285–90.
   PubMed Web of Science ®Google Scholar